Stay updated on Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Sign up to get notified when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.

Latest updates to the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page
- Check5 days agoChange DetectedThe page now shows Revision: v3.3.4 instead of v3.3.3; this update does not change any study details, eligibility, or outcomes.SummaryDifference0.1%

- Check12 days agoChange DetectedAdded Type 2 diabetes as a topic and MedlinePlus Genetics as a related topic to the page.SummaryDifference0.2%

- Check19 days agoChange DetectedType 2 diabetes is no longer listed as a condition on the page, and the MedlinePlus Genetics related topics section has been removed.SummaryDifference0.2%

- Check26 days agoChange DetectedAdded the Locations section with the Gyeonggi-do site (Seongnam-si, South Korea) and updated the revision to v3.3.3. Removed the Gyeonggi-do Locations header and the HHS Vulnerability Disclosure link in this update.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page shows an updated revision note (Revision: v3.3.2) and the previous revision (Revision: v3.2.0) has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedRemoved the government funding notice banner that warned about potential delays and updates.SummaryDifference0.4%

Stay in the know with updates to Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.